Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Mesothelioma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Melanoma 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 4belinostat 2SS1(dsFv)PE38 2Cisplatin 2venetoclax 1rovalpituzumab tesirine 1durvalumab 1cemiplimab 1budigalimab 1avelumab 1atezolizumab 1Topotecan 1Tissue Banks 1Thiotepa 1Tamoxifen 1Tablets 1Sorafenib 1Sirolimus 1Radiotherapy 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Immune Checkpoint Inhibitors 1Fluorouracil 1Filgrastim 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × budigalimab × Other solid neoplasm × Clear all
NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡